



*For Immediate Release*

## **LMA STAYS AHEAD OF COMPETITION WITH LATEST GENERATION SINGLE-USE LARYNGEAL MASK AIRWAY**

- Singapore hospitals first in Asia to see the product
- Innovative product design incorporates 18 years of clinical research and usage experience
- Sets a new standard for supraglottic airway management devices

**Singapore, 10 November 2006** – Singapore-listed LMA International NV (“LMA” or the “Group”), a global leader in the development and marketing of the LMA™ laryngeal mask airway range of supraglottic airway management devices, has unveiled the LMA Supreme™, the most advanced single-use laryngeal mask airway, in Singapore. The first country in Asia to view the product, the LMA Supreme™ was unveiled at a breakfast meeting for the local medical fraternity this morning.

The LMA Supreme™ is a convenient, safe and user-friendly single-use product which has been designed as an effective replacement for the endotracheal tube in surgical procedures involving general anaesthesia and complements LMA’s existing range of airway management devices. It incorporates 18 years of clinical research and experience from 300 million uses worldwide.

To be manufactured in Singapore, the LMA Supreme™ is the only single-use laryngeal mask with a built-in drain tube available globally. This innovative feature allows for easy gastric access and separates the alimentary and respiratory tracts enabling blind insertion of standard gastric tubes into the stomach. The product is currently available in three sizes – for children weighing between 30 to 50 kilograms, for adults weighing between 50 to 70 kilograms and for larger adults weighing between 50 to 100 kilograms.

Mr John Lim, LMA’s Group President, said, “This device will further strengthen LMA’s market position in single-use products. Not only do we expect this new device to spur conversion from reusable to single-use devices, but with improved features and patient benefits, we also expect to gain market share from the endotracheal tube. The innovative product design sets a new standard in the development of supraglottic airway management devices and propels us ahead of our competitors.”

The unique features of the device are protected by a series of more than 40 pending patent applications. Assuming that the patents are granted, the earliest expiry will occur in the year 2025.

LMA Supreme™, which is scheduled to commence manufacture by the end of this year, is expected to significantly strengthen LMA’s market position in single use devices.

- Ends -

**For media queries, please contact:**

Sharon Seetho, Gavin Anderson & Company Singapore, Tel: +65 6339 9110

**About LMA**

Incorporated in the Netherlands Antilles in 1998, LMA was listed on the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ laryngeal mask airway range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA-Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ laryngeal mask airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Bonn, Germany and San Diego, California. Through its 50 percent joint venture in LMA Urology Limited, the Group has a subsidiary in Switzerland to design, manufacture and distribute the LMA StoneBreaker™. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA.